Developing a pipeline for primary tissue assignment and individualised targeted therapy recommendations for cancers of unknown primary

University of Sussex0 个研究点目标入组 40 人开始时间: 2026年6月1日最近更新: 2026年7月13日

适应症

试验速览

暂无简介。

•Aged 18 years or over
•Written informed consent according to International Conference on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (ICH/GCP) and national regulations
•ECOG Performance status 0-2
•Suspected diagnosis of CUP as per the European Society for Medical Oncology (ESMO) guidelines, or presenting with a MOU
•Well enough for biopsy
•Patients must have:
•The local pathology reports confirming compatibility with CUP diagnosis and the associated slides used for the diagnosis
•Discussion at a local CUP Multidisciplinary Team (MDT) suspecting diagnosis
•Availability of tumour histological report

•Patient with an immunohistochemistry profile that provides a definitive clinical indication of a primary cancer with a specific treatment
•Known HIV, Hepatitis B, C positive, due to the difficulties in handling high-risk specimens
•Patients who are unable to provide fully informed written consent

发起方